Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation.

Guo J, Lam LT, Longenecker KL, Bui MH, Idler KB, Glaser KB, Wilsbacher JL, Tse C, Pappano WN, Huang TH.

Biochem Biophys Res Commun. 2017 Sep 23;491(3):681-686. doi: 10.1016/j.bbrc.2017.07.143. Epub 2017 Jul 26.

PMID:
28756225
2.

SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).

Curtin ML, Heyman HR, Clark RF, Sorensen BK, Doherty GA, Hansen TM, Frey RR, Sarris KA, Aguirre AL, Shrestha A, Tu N, Woller K, Pliushchev MA, Sweis RF, Cheng M, Wilsbacher JL, Kovar PJ, Guo J, Cheng D, Longenecker KL, Raich D, Korepanova AV, Soni NB, Algire MA, Richardson PL, Marin VL, Badagnani I, Vasudevan A, Buchanan FG, Maag D, Chiang GG, Tse C, Michaelides MR.

Bioorg Med Chem Lett. 2017 Aug 1;27(15):3317-3325. doi: 10.1016/j.bmcl.2017.06.018. Epub 2017 Jun 14.

PMID:
28610984
3.

Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors.

Wilsbacher JL, Cheng M, Cheng D, Trammell SAJ, Shi Y, Guo J, Koeniger SL, Kovar PJ, He Y, Selvaraju S, Heyman HR, Sorensen BK, Clark RF, Hansen TM, Longenecker KL, Raich D, Korepanova AV, Cepa S, Towne DL, Abraham VC, Tang H, Richardson PL, McLoughlin SM, Badagnani I, Curtin ML, Michaelides MR, Maag D, Buchanan FG, Chiang GG, Gao W, Rosenberg SH, Brenner C, Tse C.

Mol Cancer Ther. 2017 Jul;16(7):1236-1245. doi: 10.1158/1535-7163.MCT-16-0819. Epub 2017 May 3.

4.

Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.

Hopkins TA, Shi Y, Rodriguez LE, Solomon LR, Donawho CK, DiGiammarino EL, Panchal SC, Wilsbacher JL, Gao W, Olson AM, Stolarik DF, Osterling DJ, Johnson EF, Maag D.

Mol Cancer Res. 2015 Nov;13(11):1465-77. doi: 10.1158/1541-7786.MCR-15-0191-T. Epub 2015 Jul 27.

5.

Substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as multi-targeted inhibitors of insulin-like growth factor-1 receptor (IGF1R) and members of ErbB-family receptor kinases.

Wang GT, Mantei RA, Hubbard RD, Wilsbacher JL, Zhang Q, Tucker L, Hu X, Kovar P, Johnson EF, Osterling DJ, Bouska J, Wang J, Davidsen SK, Bell RL, Sheppard GS.

Bioorg Med Chem Lett. 2010 Oct 15;20(20):6067-71. doi: 10.1016/j.bmcl.2010.08.052. Epub 2010 Aug 13.

PMID:
20817523
6.

Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases.

Fidanze SD, Erickson SA, Wang GT, Mantei R, Clark RF, Sorensen BK, Bamaung NY, Kovar P, Johnson EF, Swinger KK, Stewart KD, Zhang Q, Tucker LA, Pappano WN, Wilsbacher JL, Wang J, Sheppard GS, Bell RL, Davidsen SK, Hubbard RD.

Bioorg Med Chem Lett. 2010 Apr 15;20(8):2452-5. doi: 10.1016/j.bmcl.2010.03.015. Epub 2010 Mar 7.

PMID:
20346655
7.

Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases.

Hubbard RD, Bamaung NY, Fidanze SD, Erickson SA, Palazzo F, Wilsbacher JL, Zhang Q, Tucker LA, Hu X, Kovar P, Osterling DJ, Johnson EF, Bouska J, Wang J, Davidsen SK, Bell RL, Sheppard GS.

Bioorg Med Chem Lett. 2009 Mar 15;19(6):1718-21. doi: 10.1016/j.bmcl.2009.01.086. Epub 2009 Jan 30.

PMID:
19217287
8.

Insulin-like growth factor-1 receptor and ErbB kinase inhibitor combinations block proliferation and induce apoptosis through cyclin D1 reduction and Bax activation.

Wilsbacher JL, Zhang Q, Tucker LA, Hubbard RD, Sheppard GS, Bamaung NY, Fidanze SD, Wang GT, Hu X, Davidsen SK, Bell RL, Wang J.

J Biol Chem. 2008 Aug 29;283(35):23721-30. doi: 10.1074/jbc.M708360200. Epub 2008 Jun 17.

9.

Pyrazolo[3,4-d]pyrimidines as potent inhibitors of the insulin-like growth factor receptor (IGF-IR).

Hubbard RD, Bamaung NY, Palazzo F, Zhang Q, Kovar P, Osterling DJ, Hu X, Wilsbacher JL, Johnson EF, Bouska J, Wang J, Bell RL, Davidsen SK, Sheppard GS.

Bioorg Med Chem Lett. 2007 Oct 1;17(19):5406-9. Epub 2007 Jul 25.

PMID:
17689078
10.

Advances towards the development of ATP-competitive small-molecule inhibitors of the insulin-like growth factor receptor (IGF-IR).

Hubbard RD, Wilsbacher JL.

ChemMedChem. 2007 Jan;2(1):41-6. No abstract available.

PMID:
17089440
11.

Characterization of mitogen-activated protein kinase (MAPK) dimers.

Wilsbacher JL, Juang YC, Khokhlatchev AV, Gallagher E, Binns D, Goldsmith EJ, Cobb MH.

Biochemistry. 2006 Nov 7;45(44):13175-82.

PMID:
17073439
13.

Requirements for Vav guanine nucleotide exchange factors and Rho GTPases in FcgammaR- and complement-mediated phagocytosis.

Hall AB, Gakidis MA, Glogauer M, Wilsbacher JL, Gao S, Swat W, Brugge JS.

Immunity. 2006 Mar;24(3):305-16.

14.

Vav GEFs are required for beta2 integrin-dependent functions of neutrophils.

Gakidis MA, Cullere X, Olson T, Wilsbacher JL, Zhang B, Moores SL, Ley K, Swat W, Mayadas T, Brugge JS.

J Cell Biol. 2004 Jul 19;166(2):273-82. Epub 2004 Jul 12.

15.

ERK2 enters the nucleus by a carrier-independent mechanism.

Whitehurst AW, Wilsbacher JL, You Y, Luby-Phelps K, Moore MS, Cobb MH.

Proc Natl Acad Sci U S A. 2002 May 28;99(11):7496-501.

16.

Activation of Syk protein tyrosine kinase through interaction with integrin beta cytoplasmic domains.

Woodside DG, Obergfell A, Leng L, Wilsbacher JL, Miranti CK, Brugge JS, Shattil SJ, Ginsberg MH.

Curr Biol. 2001 Nov 13;11(22):1799-804.

17.

Bacterial expression of activated mitogen-activated protein kinases.

Wilsbacher JL, Cobb MH.

Methods Enzymol. 2001;332:387-400. No abstract available.

PMID:
11305113
18.

WNK1, a novel mammalian serine/threonine protein kinase lacking the catalytic lysine in subdomain II.

Xu B, English JM, Wilsbacher JL, Stippec S, Goldsmith EJ, Cobb MH.

J Biol Chem. 2000 Jun 2;275(22):16795-801.

19.
20.

Phosphorylation of MAP kinases by MAP/ERK involves multiple regions of MAP kinases.

Wilsbacher JL, Goldsmith EJ, Cobb MH.

J Biol Chem. 1999 Jun 11;274(24):16988-94.

Supplemental Content

Loading ...
Support Center